PMID- 9486814
OWN - NLM
STAT- MEDLINE
DCOM- 19980306
LR  - 20190512
IS  - 0027-8874 (Print)
IS  - 0027-8874 (Linking)
VI  - 90
IP  - 4
DP  - 1998 Feb 18
TI  - Prognostic value of intratumoral interferon gamma messenger RNA expression in 
      invasive cervical carcinomas.
PG  - 287-94
AB  - BACKGROUND: The production of the cytokine interferon gamma (IFN gamma) by 
      activated peripheral blood mononuclear cells may be reduced in patients with 
      invasive cervical carcinoma. This study was designed to assess the prognostic 
      value of intratumoral IFN gamma messenger RNA (mRNA) levels in such patients. 
      METHODS: Biopsy specimens of primary cervical lesions were obtained from 27 
      patients with invasive squamous cell carcinoma before they received any therapy. 
      Two prognostic groups were considered: 1) a group of 14 patients who had no 
      apparent disease recurrence and who were alive 2 years after diagnosis 
      (good-prognosis group) and 2) a group of 13 patients who had disease recurrence 
      or died during the 2-year follow-up (poor-prognosis group). A competitive reverse 
      transcription-polymerase chain reaction assay was used to measure levels of IFN 
      gamma and beta actin mRNA. The expression of human leukocyte antigen (HLA) class 
      II proteins (which is stimulated by IFN gamma) in tumor cells was studied by 
      immunostaining. RESULTS: Tumor specimens from all 14 patients in the 
      good-prognosis group contained more than 10(3) IFN gamma mRNA copies per 5 x 
      10(5) beta actin mRNA copies, whereas tumor specimens from only six of the 13 
      patients in the poor-prognosis group contained this level of IFN gamma mRNA 
      (two-sided P = .006). No clear relationship was observed between levels of IFN 
      gamma mRNA and T-cell or natural killer cell infiltration in tumors; however, a 
      statistically significant association was observed between HLA class II 
      expression on tumor cells and IFN gamma mRNA levels (two-sided P = .01). 
      CONCLUSIONS: A subgroup of poor-prognosis cervical carcinoma patients who have 
      low levels of intratumoral IFN gamma mRNA was identified.
FAU - Tartour, E
AU  - Tartour E
AD  - Laboratoire d'Immunologie Clinique, INSERM U255, Institut Curie, Paris, France. 
      etartour@curie.fr
FAU - Gey, A
AU  - Gey A
FAU - Sastre-Garau, X
AU  - Sastre-Garau X
FAU - Lombard Surin, I
AU  - Lombard Surin I
FAU - Mosseri, V
AU  - Mosseri V
FAU - Fridman, W H
AU  - Fridman WH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (DNA Probes)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - J Natl Cancer Inst. 1998 Feb 18;90(4):261-3. PMID: 9486806
MH  - Carcinoma, Squamous Cell/chemistry/*immunology/pathology
MH  - DNA Probes
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Interferon-gamma/*analysis/biosynthesis/genetics
MH  - Neoplasm Invasiveness
MH  - Polymerase Chain Reaction
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - RNA, Messenger/analysis
MH  - RNA, Neoplasm/analysis
MH  - Uterine Cervical Neoplasms/chemistry/*immunology/pathology
EDAT- 1998/03/05 00:00
MHDA- 1998/03/05 00:01
CRDT- 1998/03/05 00:00
PHST- 1998/03/05 00:00 [pubmed]
PHST- 1998/03/05 00:01 [medline]
PHST- 1998/03/05 00:00 [entrez]
AID - 10.1093/jnci/90.4.287 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 1998 Feb 18;90(4):287-94. doi: 10.1093/jnci/90.4.287.